Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Target Price at $86.83

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned an average rating of “Hold” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $86.8333.

Several research analysts have weighed in on HSIC shares. Mizuho lowered their price objective on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Wells Fargo & Company increased their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Morgan Stanley reiterated an “underweight” rating and set a $64.00 price objective (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Barrington Research set a $97.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th.

Henry Schein Price Performance

NASDAQ:HSIC opened at $76.58 on Tuesday. Henry Schein has a one year low of $61.94 and a one year high of $89.29. The company has a market cap of $8.72 billion, a P/E ratio of 23.14, a P/E/G ratio of 1.92 and a beta of 0.82. The firm’s fifty day moving average price is $74.41 and its two-hundred day moving average price is $75.80. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The firm had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts expect that Henry Schein will post 5.32 earnings per share for the current year.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks highlighted Henry Schein as a strong momentum stock, which can attract short-term traders and support sentiment around the shares. Here’s Why Henry Schein (HSIC) is a Strong Momentum Stock
• Positive Sentiment: Analyst commentary remains constructive on the company’s dental and medical distribution scale, digital dentistry strategy, and acquisition opportunities, which could support longer-term growth. Is This the Right Time to Keep HSIC Stock in Your Portfolio?
• Positive Sentiment: Henry Schein’s recent quarterly results beat estimates, with earnings of $1.32 per share and revenue of $3.37 billion topping expectations, reinforcing confidence in current operating performance.
• Neutral Sentiment: The company presented at the Stifel Jaws & Paws Conference, but the transcript does not appear to include a major new catalyst that would significantly change the stock’s near-term outlook. Henry Schein, Inc. (HSIC) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Negative Sentiment: Zacks Research trimmed several future earnings estimates for Henry Schein, including Q3 2026, Q4 2026 and Q4 2027, which may pressure sentiment by signaling slightly softer profit expectations ahead.
• Negative Sentiment: Analysts continue to flag debt and broader macroeconomic headwinds as key risks, which could limit upside if operating trends weaken.

Insider Activity at Henry Schein

In other news, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total transaction of $478,740.00. Following the sale, the executive vice president directly owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William K. Daniel bought 10,000 shares of Henry Schein stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 56,780 shares of company stock worth $4,592,830 in the last quarter. 0.89% of the stock is currently owned by corporate insiders.

Institutional Trading of Henry Schein

Large investors have recently bought and sold shares of the business. CYBER HORNET ETFs LLC acquired a new stake in Henry Schein in the second quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the second quarter valued at about $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein in the fourth quarter valued at about $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein in the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Henry Schein in the fourth quarter valued at about $37,000. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.